Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Orchestra BioMed Holdings Inc (NASDAQ: OBIO) was $2.44 for the day, down -2.79% from the previous closing price of $2.51. In other words, the price has decreased by -$2.79 from its previous closing price. On the day, 0.55 million shares were traded. OBIO stock price reached its highest trading level at $2.52 during the session, while it also had its lowest trading level at $2.42.
Ratios:
Our analysis of OBIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.09 and its Current Ratio is at 2.10. In the meantime, Its Debt-to-Equity ratio is 56.38 whereas as Long-Term Debt/Eq ratio is at 54.17.
On March 20, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $12.
On January 02, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $16.Barclays initiated its Overweight rating on January 02, 2025, with a $16 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 19 ’25 when Aryeh Jason bought 1,000 shares for $2.45 per share. The transaction valued at 2,450 led to the insider holds 108,482 shares of the business.
Fain Eric S bought 5,760 shares of OBIO for $15,034 on Aug 25 ’25. The Director now owns 71,709 shares after completing the transaction at $2.61 per share. On Aug 25 ’25, another insider, Sherman Darren, who serves as the insider of the company, bought 3,000 shares for $2.62 each. As a result, the insider paid 7,860 and bolstered with 926,837 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OBIO now has a Market Capitalization of 131650408 and an Enterprise Value of 114080408. For the stock, the TTM Price-to-Sale (P/S) ratio is 44.78 while its Price-to-Book (P/B) ratio in mrq is 319.79. Its current Enterprise Value per Revenue stands at 38.75 whereas that against EBITDA is -1.608.
Stock Price History:
The Beta on a monthly basis for OBIO is 0.59, which has changed by -0.49272346 over the last 52 weeks, in comparison to a change of 0.1653893 over the same period for the S&P500. Over the past 52 weeks, OBIO has reached a high of $6.50, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is -12.36%, while the 200-Day Moving Average is calculated to be -34.40%.
Shares Statistics:
OBIO traded an average of 326.38K shares per day over the past three months and 217330 shares per day over the past ten days. A total of 53.96M shares are outstanding, with a floating share count of 42.00M. Insiders hold about 22.15% of the company’s shares, while institutions hold 34.92% stake in the company. Shares short for OBIO as of 1756425600 were 774174 with a Short Ratio of 2.37, compared to 1753920000 on 506574. Therefore, it implies a Short% of Shares Outstanding of 774174 and a Short% of Float of 2.26.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Orchestra BioMed Holdings Inc (OBIO) in the stock market.The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.33 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$1.67 and -$2.11 for the fiscal current year, implying an average EPS of -$1.89. EPS for the following year is -$1.67, with 6.0 analysts recommending between -$1.37 and -$2.0.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $800k to a low estimate of $650k. As of. The current estimate, Orchestra BioMed Holdings Inc’s year-ago sales were $987kFor the next quarter, 5 analysts are estimating revenue of $846.2k. There is a high estimate of $1.4M for the next quarter, whereas the lowest estimate is $650k.
A total of 6 analysts have provided revenue estimates for OBIO’s current fiscal year. The highest revenue estimate was $3.8M, while the lowest revenue estimate was $3M, resulting in an average revenue estimate of $3.31M. In the same quarter a year ago, actual revenue was $2.64MBased on 6 analysts’ estimates, the company’s revenue will be $3.65M in the next fiscal year. The high estimate is $5M and the low estimate is $2.6M.
